Please add new claims 36-44 as follows:

-- 36. (New) A pharmaceutical composition comprising a human or canine replication defective recombinant adenovirus comprising a suicide gene impregnated in a hydrogel in an amount effective for inhibiting a decrease in luminal diameter of an atheromatous blood vessel when administered to a site of physical damage to said blood vessel.

37. (New) The pharmaceutical composition of claim 37, wherein the adenovirus infects at least 0.2% of smooth muscle cells of the neointima.

38. (New) The pharmaceutical composition of claim 36, wherein said replication defective recombinant adenovirus comprises:

a suicide gene operably linked to a promoter controlling expression of said gene in infected cells;

a left and a right inverted terminal repeat (ITR); and

an encapsidation signal.

39. (New) A device for percutaneous administration of a therapeutic gene, said device comprising a balloon catheter coated with a hydrogel impregnated with a defective recombinant adenovirus comprising said gene, wherein said defective recombinant adenovirus is present in an amount effective for inhibiting a decrease in luminal diameter of an atheromatous blood vessel when administered to a site of physical damage to said blood vessel.

40. (New) The device of claim 39, wherein said defective recombinant adenovirus comprises:

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

a suicide gene operably linked to a promoter controlling expression of said gene in infected cells;

a left and a right inverted terminal repeat (ITR); and

an encapsidation signal.

41. (New) A method for inhibiting a decrease in luminal diameter of an atheromatous blood vessel, said method comprising administering a therapeutic gene to said atheromatous blood vessel using a device comprising a balloon catheter coated with a hydrogel impregnated with a defective recombinant adenovirus comprising said therapeutic gene,

wherein said defective recombinant adenovirus is present in an amount effective for inhibiting a decrease in luminal diameter of said atheromatous blood vessel when administered to a site of physical damage to said blood vessel.

42. (New) The method of claim 41, wherein said defective recombinant adenovirus comprises:

a suicide gene operably linked to a promoter controlling expression of said gene in infected cells;

a left and a right inverted terminal repeat (ITR); and

an encapsidation signal.

43. (New) The method of claim 41, wherein the adenovirus infects cells in the artheromatous blood vessel.

44. (New) The emthod of claim 43, wherein 95% of the cell infected are smooth muscle cells.--

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202 408 4000
Fax 202 408 4400
www.finnegan.com